Picture a site coordinator on a Tuesday morning pulling the binder she built for the last BIMO inspection — tabbed, cross-referenced, organized across three days of reviewer questions. That binder took four weeks to assemble and assumed a standard FDA inspection cadence: arrival, document review, data audit, investigator interview, closeout. Now picture a single FDA investigator walking through the door with a single day on the calendar. That binder, and the readiness strategy behind it, was engineered for a format that may no longer be the default.
The FDA launched its one-day inspectional assessments pilot program in April 2026, framing the compressed visits as a complement to traditional full inspections rather than a replacement. The stated goal is broader surveillance coverage with more targeted deployment of inspectional resources. What the press announcement does not spell out — but every clinical operations team should be reading into — is that the agency is now explicitly sorting facilities into tiers before an investigator ever boards a plane. The triage is happening earlier than sites have historically assumed, and the evidence used to make that triage decision will define who gets a one-day screening and who gets the full inspection that follows.
The Resource Gap Driving This
The pilot did not arrive without context. According to a GAO analysis, the FDA conducted 1,065 total inspections in fiscal year 2023 — a 40% increase over fiscal year 2022, but still significantly below the 1,671 inspections completed in fiscal year 2019, the last full year before pandemic disruptions reshaped field operations. The agency has been operating with a structural inspection deficit for five years. The one-day pilot is a direct operational response to that gap: if you cannot increase inspector headcount fast enough to close the backlog, you redesign the inspection format to extend coverage.
That logic is defensible from a resource allocation standpoint. But it creates a practical problem for sites that have calibrated their readiness programs to the traditional inspection format, which typically runs three to five days for a clinical site and involves layered document review, staff interviews, and protocol-specific data audits. A one-day assessment compresses all of that into a focused screening — which means the investigator arrives with a prioritized question set, not an open-ended review agenda.
The counterintuitive implication here is worth naming directly: compressed inspections do not reduce the compliance burden on sites. They concentrate it. A five-day inspection allows a site to surface documents progressively, answer clarifying questions, and course-correct a narrative as the visit unfolds. A one-day assessment demands that the most critical compliance evidence be immediately retrievable, clearly organized, and self-explanatory without investigator prompting. Sites that have treated readiness as a reactive process — assemble the binder when the phone rings — are now facing a format where assembly time has been eliminated from the equation.
What the One-Day Format Actually Tests
The FDA’s press announcement on the pilot program describes the one-day assessments as targeting lower-risk establishments and providing timely feedback for industry. Read that carefully. “Lower-risk” is a pre-classification, which means the agency is forming a risk profile of your site before the assessment begins — drawing on prior inspection history, warning letters, 483 observation patterns, and likely the site’s participation record in high-scrutiny therapeutic areas.
For clinical trial sites specifically, the implications land hardest on three operational areas: eClinical system documentation, CAPA status and effectiveness, and vendor oversight records. Each of these tends to be the category where sites have the most documentation — and the worst retrieval architecture. A coordinator who can find the most recent ICF version in thirty seconds during a monitoring visit may need four separate system logins to produce a complete audit trail for an EDC change log, an eISF completeness report, and a 21 CFR Part 11 access control record in the same timeframe.
The FDA’s guidance on 21 CFR Part 11 electronic records and electronic signatures — regulations in place since March 1997 — requires that electronic systems used in clinical investigations maintain audit trails that capture operator identification, date, time, and reason for change. In a standard BIMO inspection, an investigator might spend half a day working through those audit trails with a system administrator present. In a one-day assessment, that same review may need to happen in under two hours. Sites whose eTMF and EDC systems are not configured for rapid, role-specific audit trail export will lose those two hours to navigation rather than demonstration.
Across sites in our network, the single most common gap we see in inspection readiness is not missing documentation — it is documentation that exists in three places and is authoritative in none of them. The one-day format punishes exactly that pattern, because there is no time for a coordinator to explain which version of a CAPA closure record is the final one.
Rewriting the Readiness Playbook Now
The practical response for clinical operations teams is not to build a shorter binder. It is to restructure readiness around the assumption that any inspection could be a one-day assessment, regardless of the site’s perceived risk tier.
Start with retrieval architecture, not document completeness. Every site should be able to produce, within thirty minutes of an investigator’s arrival: the current IRB approval with expiration date, the most recent monitoring visit report and its open findings log, the active CAPA register with status and effectiveness check dates, the eTMF completeness percentage from the last internal audit, and the vendor oversight log for any central lab, central IRB, or ePRO vendor active on current studies. Not because these are the only documents an FDA investigator will request — but because an inability to produce these immediately signals to an assessor that deeper review is warranted, which is precisely the outcome that converts a one-day screening into a full inspection follow-up.
Sponsor-side clinical operations teams carry their own exposure here. If a site is flagged during a one-day assessment and escalated to a full BIMO inspection, the sponsor’s oversight documentation for that site becomes part of the inspection record. ICH E6(R3), finalized in 2023, places explicit accountability on sponsors for risk-proportionate monitoring and documented site oversight — and an FDA investigator reviewing a sponsor’s monitoring visit reports against a site’s deviation log during a full inspection will be asking whether the sponsor saw the same gaps the assessor found in one day. If the monitoring visit reports show “no significant findings” at a site that produces a disorganized readiness response, that discrepancy becomes its own compliance question.
The one-day assessment pilot will likely produce a sorting effect across the site landscape within the next twelve to eighteen months: sites that have invested in retrieval infrastructure and continuous readiness will move through assessments without triggering escalation, while sites running on reactive readiness will convert one-day screenings into full inspections at a higher rate — and with less preparation time than a traditional BIMO notice would have provided. Watch whether the FDA publishes aggregate findings data from the pilot. If the agency reports escalation rates by site type or therapeutic area, that data will define the next generation of site qualification criteria for sponsors who are paying attention.
References
- FiercePharma — “FDA rolls out 1-day assessment pilot in bid to refocus inspection resources”
- FDA — “FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight” (April 2026)
- The FDA Group — “GAO: FDA Should Implement Strategies to Address Inspection Shortfalls” (citing FY2023 inspection data)
- FDA — “Part 11, Electronic Records; Electronic Signatures — Scope and Application” guidance
